Reduced Weight Regain: CCT-217 shows promise in preventing weight regain commonly observed after discontinuing incretin ...

A prolific medical research and author, Martin Makary criticized the FDA and CDC for their decision-making during the ...

The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market ...

Evotec appears to have rebuffed Halozyme’s $2.1 billion acquisition attempt. Elsewhere, Argenx has another blockbuster target ...

The restructuring follows the company's receipt of a letter from the FDA citing "deficiencies" in its approval application ...

The company paused testing of one candidate acquired in its April deal for Escient and scrapped another in a blow to its ...

Despite plans to shutter 1,200 stores, the company’s chief clinical trials officer said the pharmacy giant remains committed ...

In buying Westlake-backed Kate Therapeutics, Novartis gets a handful of preclinical gene therapies targeting diseases like ...

Venture capital firms incubate, grow and finance dozens of drug companies each year. Follow the money they channel into the ...

Howard Chang will take over as chief scientific officer and senior VP of research as the biotech searches for more ways to ...

The startup, Pep2Tango, is combining four methods of accelerating weight loss into one medicine in the hopes of developing a ...